FTC sues big pharmacy reward supervisors more than insulin costs The agency brought action from Caremark, Categorical Scripts and Optum Rx, arguing their “anticompetitive and unfair” rebating tactics “artificially inflated” the listing cost of daily life-conserving insulin medicines. This approach aligns with those attempts, the ONC explained. The field is https://arizonahardnutritionfacts05059.blogcudinti.com/30638603/healthcare-news-an-overview